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Summary Progression through G, phase of the eukaryotic cell cycle is tightly controlled by cyclin-dependent kinases (CDK). These proteins
form part of a regulatory pathway including the cyclin-dependent kinase inhibitor (CKI) p16, D-type cyclins and the product of the
retinoblastoma gene pRb. Aberration of any one of these components may lead to uncontrolled proliferation contributing to neoplasia. Three
of these proteins, cyclin Dl, pRb and p16, were analysed by immunohistochemistry on archival paraffin sections to determine whether
expression patterns were different in preinvasive ductal carcinoma in situ (DCIS) and invasive breast tumours relative to normal. Genetic
analysis of the gene encoding cyclin Dl (CCND1) was also carried out, using an intragenic restriction fragment-length polymorphism (RFLP)
to assess possible allelic imbalance. A majority of the tumours studied (-90%) showed abnormalities in expression of at least one of these
proteins. Overexpression of cyclin Dl was found in -49% cases, reduced expression of p16 in -46% and reduced expression of pRb in
-37%. Allelic imbalance of cyclin Dl was found in -57% cases.
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Proliferation of mammalian cells is tightly controlled by a check-
point in G, phase known as the 'restriction point', progression
through which commits the cell to entering S-phase and
completing the round of cell division. Proteins involved in this
control include the cyclin-dependent kinases (CDK), which, when
activated by binding to acyclin, drive cell proliferation in response
to growth signals transduced from the extracellular environment
by phosphorylating pRb. This inactivates the growth-restraining
function ofpRb by releasing transcription factors required to acti-
vate S-phase genes, which had been physically sequestered by
pRb. The important role played by the D-type cyclins is reflected
by the fact that, when anti-cyclin Dl antibodies are microinjected
in early tomid-G, phase, most tumour and normal cell types arrest
before S-phase (Lukas et al, 1994).
GI phase progression is negatively regulated by the cyclin-
dependent kinase inhibitors, a recently identified group ofproteins
that bind to and inhibit the kinase activity of CDKs. p16 is one
suchprotein that specifically affects cyclin D-CDK4 and cyclin D-
CDK6 and is able to block G1-S progression.
The G1 checkpoint may, if defective, lead to deregulated
growth, and aberrations in some of these specific cell cycle genes
are increasingly being found in malignant cells. It appears that the
cell cycle control pathway governed by the D-type cyclins is the
most commonly mutated pathway in tumour cells (Lukas et al,
1995a). Perturbation ofany individual component is likely to have
a similar oncogenic effect, for example amplification and/or over-
expression ofcyclin Dl (Lammie et al, 1991; Nishida et al, 1994;
Nakagawa et al, 1995), amplification or mutation ofCDK4 (He et
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al, 1995) and loss ofp16 (Reed et al, 1995; Sonodaet al, 1995) and
pRb (Harbour et al, 1988; Geradts et al, 1994).
These cell cycle components have been studied by various
means in invasive breast tumours. Cyclin DI is found within chro-
mosome band 1lq13, which is amplified in -15-20% of primary
breast cancers (Fantl et al, 1990; Lammie et al, 1991), and over-
expression of cyclin Dl at the mRNA level has been reported for
an even greater proportion ofbreast cancers (Buckley et al, 1993).
More recently, it has been possible to look directly at cyclin Dl
protein expression by means of immunohistochemistry using a
monoclonal antibody to the protein. Approximately halfofprimary
breast carcinomas studied showed overexpression/accumulation of
the cyclin Dl protein (Bartkova et al, 1994; Gillett et al, 1996).
The relationship between the Rb gene and breast cancer is
complex, with loss of heterozygosity of the Rb locus not neces-
sarily being related to mutation orphysical deletion ofthe Rb gene
or to reduced expression of the protein (Borg et al, 1992;
Wadayama et al, 1994; Berns et al, 1995). Consequently, studies
onpRb expression may yield more information on the roleofRb in
breast cancer. Loss ofpRb expression has been found to correlate
with more advanced and less differentiated mammary tumours
(Varley et al, 1989).
The role played by p16 in breast carcinogenesis is also unclear.
Despite the initial discovery of homozygous deletions of p16 in
human tumour cell lines, including those derived from invasive
breast tumours, mutational analysis ofprimary breast tumours indi-
cated thatmutations ofp16inbreasttumours arerare (Xuetal, 1994;
Brenner and Aldaz, 1995). Therefore, direct analysis of the p16
protein by immunohistochemistry was again expected to yield more
relevant information than could be obtained from genetic analysis.
Work on preinvasive breast lesions has been more limited. In
this study, three panels of tumours were available: purely in situ
tumours (DCIS), invasive tumours with a DCIS component and,
for comparison, purely invasive tumours. Immunohistochemical
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Figure 1 Restriction fragment-length polymorphism within the cyclin Dl
gene. Primers Cy26-Cy27 amplify a fragment of the cyclin Dl gene, which
contains a polymorphic restriction site recognized by the ScrFl restriction
enzyme. PCR products are digested with the enzyme and run on an agarose
gel to separate alleles of different size (allele A: 167 bp; allele G: 145 bp).
The intensity of the alleles in a heterozygous tumour are assessed for signs
of imbalance relative to normal
analysis ofcyclin Dl, pRb andp16 was carried out on all three sets
and results compared. In addition, afurtheraspect to the regulation
of cyclin Dl expression was assessed by determining possible
allelic imbalance of the gene, with reference to an intragenic
restriction fragment-length polymorphism.
MATERIALS AND METHODS
Tumour samples
Formalin-fixed, paraffin-embedded tumour tissue from three
separate tumour sets was obtained from Withington and Christie
Hospitals, Manchester. Sections from ten invasive breast cancer
cases, 13 cases ofpure DCIS and 18 cases containing both an inva-
sive and an intraductal component were suitable for immunohisto-
chemical analysis. Allelic imbalance studies were carried out on
DNA from 20 invasives, 12 DCIS and ten DCIS/invasive cases,
some of which had been included in the immunohistochemical
analysis.
Analysis of allelic imbalance of the cyclin Dl gene
The recent identification of a polymorphism within the cyclin DI
coding sequence (Betticher et al, 1995) enabled analysis of allelic
imbalance of the gene in archival material by means of the poly-
merase chain reaction (PCR). The single base pair A/G polymor-
phism creates a restriction site that is cleaved by the restriction
enzyme ScrFI when the variant G base is present. The level of
heterozygosity of this restriction fragment-length polymorphism
(RFLP) was predicted to be 49%. Primers Cy 26 and Cy 27 were
designed to allow PCR amplification of this region of the gene
Table 1 Results of cyclin Dl allelic imbalance and overexpression study
(A) Invasive breast cancer cases
Case number
76 127 129 139 161 163 166 219 228 330 343 344 353 364 369 370 374 389 395 413
RFLP GG GA GG GG GA GG AA AA GA GA GG GA GG GA GG GG GG AA AA GG
Allelic imbalance - - - v - - - ( x - x - x
Expression ++ + NA NA +++ +++ NA NA + + +++ ++ NA NA NA NA NA NA x +++
(B) DCIS cases
Case number
2652 2969 4419 6050 2238 2239 2242 3812 601 6092 1960 2659
RFLP GG GA M GA GG GG GG GG AA AA GG GA
Allelic imbalance - x - x - - - - - - - D1/2
Expression ++ ++ ++ ++ ++ ++ x ++ + +++ + ++
(C) DCIS/invasive cases
Case number
3144 6457 452 3041 4410 6256 6384 613 2753 2931
RFLP GA GA AA GG AA GA GA GG GA GG
DCIS/invasive D D D D D D D D D D
Allelicimbalance / / / / - - - - - - x I / x - - x x - -
Expression + ++ ++ ++ + + +++ +++ + + x x + + +++ +++ +
(A) Invasive breast cancer cases showing RFLP status; presence (/) or absence (x) ofallelic imbalance in cases heterozygous for the ScrFl polymorphism;
(-) homozgyous cases therefore no allelic imbalance; degree of expression of cyclin Dl protein: no expression (x), weak (+), moderate (++) or strong (+++);
NA, information not available; blank, not tested. (B) DCIS cases. (C) DCIS/invasive cases.
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Table 2 Results of immunohistochemistry on paraffin sections: expression of retinoblastoma, cyclin Dl and p16 proteins.
(A) Invasive cases
Case number Expression of pRb Expression of cyclin Dl Expression of p16 Aberrant
component
Intensity Location Intensity Location Intensity Location
76 ++ N/C ++ C/N ++ C Cyclin Dl
127 ... N/C + C + C p16
161 ... N/C ++ N/C ... C/N Cyclin Dl
163 +++ N/C +++ N/C ++ C/N Cyclin Dl
228 ... N/C + C +++ C/N -
330 +++ N/C + C - - p16
343 ++ N/C ++ C ++ C/N Cyclin Dl
344 ++ N/C ++ C ++ C Cyclin Dl
395 ++ C/N - - + C p16
413 ... N/C +++ C/N ++ C Cyclin Dl
(B) DCIS cases
Case number Expression of pRb Expression of cyclin Dl Expression of p16 Aberrant
component
Intensity Location Intensity Location Intensity Location
2652 +++ C ++ C ++ C pRb+ D1
2969 ++ C + C + C pRb + p16
4419 +++ C/N ++ C ++ C Cyclin Dl
6050 - - ++ N/C - - pRb + D1 + p16
2238 +++ C/N ++ C +++ C Cyclin Dl
2239 +++ N/C ++ C/N ++ C/N Cyclin Dl
2242 +++ C/N - - + C p16
3812 + C ++ C/N ++ C pRb + D1
601 + C/N + C/N - - pRb + p16
6092 ++ C/N +++ C/N ++ C/N Cyclin Dl
1960 + C + C +++ C pRb
2659 ++ C/N ++ C/N ++ C/N Cyclin Dl
4842 ++ C/N ++ C/N + C D1 + p16
(C) DCIS/invasive cases
Case number Expression of pRb Expression of cyclin DI Expression of p16 Aberrant
component
Intensity Location Intensity Location Intensity Location
D I D I D I D I D I D I
3144 +++ + N/C C + C/N +++ C/N pRb
4617 + + C C + + C C - - pRb+p16
6457 + + C C ++ ++ C/N C/N + + C/N C/N pRb + D1 + p16
452 + + C N/C ++ ++ N N +++ +++ C/N C/N pRb + D1
458 + + C/N C/N - - - - +++ C/N pRb
593 + + C/N C/N + + C C ++ ++ C/N C/N pRb
1141 + + C C + - C - - - - - pRb + p16
3041 ++ + N/C C + + C C +++ +++ C/N C/N pRb
4410 - - - - +++ +++ N N ++ + C C pRb + p16 + D1
6045 + + C C + + C C ++ C pRb
6256 + + C C + + C C ++ + C C pRb + p16
6384 + + C C ++ ++ N N ++ ++ C/N C/N pRb + D1
613 - - - - + + C C + + C C pRb + p16
1565 ++ ++ N/C N/C + + C/N C/N ++ ++ C C -
2753 +++ +++ N/C N/C +++ +++ C/N C/N +++ +++ C C Cyclin Dl
2931 ++ ++ N/C N/C + + C C ++ + C C p16
2939 ++ ++ N/C N/C + C +++ C/N -
2996 ++ ++ N/C N/C ++ ++ N/C N/C ++ ++ C C Cyclin Dl
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(A) Invasive cases. (B) DCIS cases. (C) DCIS/invasive cases. Staining intensity scored as absent (-), weak (+), moderate (++) or strong (+++). Both
cytoplasmic (C) and nuclear (N) staining patterns were observed, with C/N representing predominantly cytoplasmic staining plus <50% positive nuclei and N/C
representing >50% positive nuclei plusvarying degrees of cytoplasmic staining.
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containing the restriction site: Cy 26 5' GTG AAG TTC ATT TCC
AAT CCG C-3'; Cy 27 5'-GGG ACA TCA CCC TCA CTT AC-
3'. The arrangement of these primers is shown in Figure 1.
Reactions were carried out in a final volume of 50gl containing
lx PCR buffer, 250gM dNTPs, 6 ng p1l- each of forward and
reverse primer and 0.5-2 units Thermoprime plus DNA poly-
merase (Advanced Biotechnologies). Normal and tumour DNA
from each case was used as template, either 2-5 pl of DNA
extracted from microdissected tissue or 1 gl of blood/tumour
DNA from the invasive breast cancer cases. Reaction conditions
included an initial denaturation step of 94°C for 4 min followed
by 37 cycles each of94°C for 1 min, 60°C for 1 min and 74°C for
1 min with a final extension step of72°C for 10 min.
Twenty microlitres ofPCR product were digested with 1 unit of
ScrFI restriction enzyme in lx enzyme buffer in a total volume of
50 ,l. After incubation at 37°C for 3 h, digestion products were
visualized on a 2% agarose gel. Cases heterozygous for this RFLP
showed two fragments afterdigestion. These could be assessed for
allelic imbalance of cyclin DI, by comparison of the intensity of
the alleles in the tumour compared with normal.
Immunohistochemistry
Formalin-fixed paraffin sections (4,M) were prepared on 3-
aminopropyltriethoxysilane-coated slides. After dewaxing in
xylene, the sections were immersed in 300 ml of methanol
containing 10 ml of hydrogen peroxide for 15 min to block
endogenous peroxidase and then were rinsed thoroughly in water.
When using the antibodies to cyclin Dl and pRb the sections were
placed in citrate buffer (pH 6.0) and boiled for 5 min in a
microwave. The solution was allowed to stand for 5 min before
bringing to the boil again, for a further 5 min. Once the buffer had
cooled to room temperature, the slides were washed well with
water and rinsed in Tris-buffered saline (TBS, pH 7.6). Sections
were covered with 1:100 goat serum for 20 min at room tempera-
ture. This was removed by tapping the slides on absorbent paper,
rather than by further washing. Sections were then incubated
overnight at room temperature in a humidified container, with
either primary antibody or goat serum as a negative control to
confirm the specificity ofthe immunostaining reaction.
The mouse monoclonal cyclin Dl antibody DCS-6 (Novocastra)
was used at a 1:100 dilution in 1% bovine serum albumin (BSA) and
the mouse monoclonal pRb antibody (NCL-RB1, Novocastra) was
used at a 1:50 dilution in 1% BSA. The mouse monoclonal anti-
human p16 antibody (Pierce) was diluted 1:150 in TBS and was
used in a similar protocol to that described above, but omitting the
antigen retrieval step. Primary antibody was removed by two
washes withTBS, eachfor3 min. This was thenreplaced with 1:100
biotinylated goat anti-mouse/rabbit Ig (Dako) for 30 min at room
temperature. After afurthertwo washes with TBS, the sections were
incubated in 1:100 solution of streptavidin-biotin complex/horse-
radish peroxidase (Dako) for 30 min atroom temperature, rewashed
in TBS twice and covered in 3,3'-diaminobenzidine tetrahydro-
chloride (1 mg ml-' DAB, Dako) for 10 min. After a thorough rinse
in water, sections were counterstained with 2x Gills haematoxylin,
washed in water, cleared, dehydrated and mounted.
Assessment of staining patterns
Staining was assessed according to the intensity ofthe majority of
cells and particular attention was paid to the localization of the
staining; cytoplasmic or nuclear. For the cyclin Dl staining,
comparisons were made with the staining pattern of a positive
control for cyclin D1; a breast carcinoma known to overexpress
cyclin D1. For the p16 staining, a negative control for p16, the
breast carcinoma cell line MDA-MB-231, which has a deletion of
p16, was included. A description of the observed staining pattern
was noted and cases graded accordingly. All cases were rescored
to confirm the initial result and a selection of cases was indepen-
dently assessed by an experienced histopathologist (Dr F Knox)
for further confirmation.
The criteria for a 'normal' staining pattern was dependent on the
protein being studied. For cyclin D1 when normal ducts were
present on the section, the staining pattern in these cells was
considered to be normal and used as a comparison to the staining
pattern observed in the ducts containing DCIS or invasive tumour.
In the absence of normal ducts, stromal cells were observed for
evidence of staining. A normal staining pattern was scored as '+'
or '-' and overexpression was considered to be '++' or '+++'. In
contrast, Rb is known to function as a tumour suppressor and as
such is expected to be expressed in normal cells. For those cases in
which normal ducts were present, pRb staining was observed in
the nucleus, and this was classed as a 'normal' staining pattern,
represented as '++' or '+++'. Alternatively, stromal cells and
fibroblasts were often positively stained and this too was taken as
anormal internal control. Similarly, when scoring sections forp16,
anormal staining pattern was taken to be ofmoderate/strong inten-
sity (++, +++), although for some tumours scored as '+++' this
represents an apparent increase in p16 protein relative to normal
cells from the same case. For those cases showing only cyto-
plasmic staining in the normal ducts and a similar pattern in the
tumour cells, this too wasjudged to be normal in this study.
RESULTS
Allelic imbalance of the cyclin Dl gene
A total of 14 out of 42 (-33%) PCR products amplified with
primers Cy 26 and Cy 27 were heterozygous for the ScrFH poly-
morphism as shown in Table 1. These cases were assessed for
allelic imbalance in the tumour, which would appear as an
increased/decreased intensity in one allele relative to the other
allele in the tumour and relative to the same allele in the normal
DNA. Such imbalance was found in eight cases (57%), some of
which have allelic imbalance in more than one component of the
same tumour, such as case 6457. This was assumed to be represen-
tative of amplification of the cyclin Dl gene, as there is much
evidence to suggest that cyclin DI behaves as an oncogene and a
number ofprevious studies have shown the gene to be activated by
amplification (Fantl et al, 1990; Lammie et al, 1991).
Information gained from this technique was then complemented
by immunohistochemical analysis of the cyclin DI protein and
other cell cycle proteins.
Results of immunohistochemistry
Results from each of the three tumour sets stained with all three
antibodies are represented in Table 2.
Expression of cyclin Dl
Representative photographs showing the range ofstainingpatterns
observed with the antibodies to cyclin DI are shown in Figure
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Figure 2 Representative photographs of staining patterns. (A-C) Staining for cyclin Dl. (A) Normal ducts showing no staining. (B) DCIS case 6050 showing
overexpression (++ N/C) of cyclin Dl. (C) Invasive case 343 showing cytoplasmic staining (++ C). Magnification x100. (D and E). Staining for pRb. (D) Case
127 showing normal staining pattern (+++ N/C) in invasive tumour cells, x400. (E) Case 1960 showing reduced expression (+ C) of pRb in DCIS, x100. (F)
Staining for p16. Case 2753 showing strong cytoplasmic staining (+++ C) in invasive tumour, x100
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2A-C. Staining patterns varied from predominantly nuclear with a
small background level of cytoplasmic staining to predominantly
cytoplasmic with only a small percentage of positive nuclei, to
equally strong staining in both the nucleus and the cytoplasm, to
exclusively cytoplasmic staining or to no staining at all. The posi-
tive control breast carcinoma known to overexpress cyclin DI
invariably showed positive nuclear staining of a proportion of
cells. The no-antibody negative controls included for each section
did not show any staining.
The results ofthe genetic and immunohistochemical analysis of
cyclin Dl carried out in this study are reasonably consistent with
previous work looking at amplification of the gene and over-
expression ofthe protein in human breast cancer. The finding that
increased protein expression is not always accompanied by gene
amplification and that some cases with amplification do not show
increased expression (Table 1) is in agreement with the results of
a study by Buckley et al (1993). This study provides additional
information on purely DCIS lesions and invasive lesions with an
intraductal component. In contrast to many previous studies on a
range of malignancies (Bartkova et al, 1994, 1995; Michalides et
al, 1996), which have reported predominantly nuclear staining and
tended to regard cytoplasmic staining as an insignificant artefact,
the cyclin DI protein in this study was frequently observed at high
levels within the cytoplasm. Taking into account the strength of
staining, combined with the marked contrast in staining results
obtained from material prepared in the same way, it is reasonable
to assume that strong cytoplasmic staining in one case compared
with weak cytoplasmic staining in another case does reflect a true
difference in expression ofthe cyclin DI protein between the two
tumours and is unlikely to be as a result of the fixation. A similar
pattern of exclusively cytoplasmic staining, or cytoplasmic
staining in combination with nuclear staining, has previously been
observed in non-small-cell lung cancers (Betticher et al, 1996). In
addition, an earlier in vitro study looking at expression of cyclin
Dl and D2 (Lukas et al, 1995b) in U-2-OS sarcoma cells found
both proteins to have a subcellular nuclear localization during mid
to lateGp, in contrast to a cytoplasmic and nuclear localization at
the G,-S transition. The possible reason given for this was a
change of solubility of the proteins, due to a loss of a selective
nuclear anchor at theG,-S transition.
Expression of pRb
A range ofstaining patterns was observed for pRb and is shown in
Figure 2D and E. Commonly, strong nuclear staining was apparent
in a majority ofcells, accompanied by some cytoplasmic staining.
However, in some cases nuclear staining was visible in only a
small proportion ofcells, whereas strong cytoplasmic staining was
visible in all cells. Exclusively cytoplasmic staining was scored as
loss of pRb. Abnormally low levels of pRb in the nucleus were
considered to be '+' or '-', a pattern that is seen in 19 (-46%)
cases in total (Table 2). As this is likely to lead to a loss in the
'brakes' on the cells' proliferation, reduced expression ofpRb may
have played some part in the progression to neoplasia.
Expression of p16
Despite the fact that like pRb, p16 is a tumour suppressor and is
thought to carry out its functions within the nucleus, many sections
had evidence of cytoplasmic staining, sometimes alone (Figure
2F) and sometimes in combination with nuclear staining. When
this cytoplasmic staining was weak '+', it was considered to be
residual non-specific staining. However, for several cases, the
intensity ofthe cytoplasmic staining was such that it could not be
ignored. As antibodies for p16 are relatively new, information on
staining patterns found in various tissues and tumours is limited. In
addition, much remains to be learned about the expression patterns
and functions of pI6. Fifteen cases (-37%) showed reduced
expression ofp16 relative to normal.
Relationship between expression of cyclin DI, pRb
and p16
There is evidence to suggest that both pRb and cyclin DI are
involved in an autoregulatory feedback loop mechanism that
controls progression through GI phase. It has been observed that
Rb-deficient tumour cell lines have very low levels of cyclin DI
(Muller et al, 1994) and cyclin D/CDK complexes (Bates et al,
1994). As can be seen from the results in Table 2, this type of
correlation has been observed in a number ofcases from this study,
with notable exceptions. Twelve of the 15 cases showing reduced
expression of pRb (80%) have a correspondingly low level of
cyclin Dl expression ('+' or '-'), including case 1960 and case
613, providing support for an autoregulatory relationship between
cyclin Dl and pRb. In contrast to this, the remaining three cases
showing low pRb levels have varying degrees of cyclin Dl over-
expression, for example case 4410, which has strong nuclear
positivity for cyclin DI in a majority ofcells.
A number of studies have also reported an inverse relationship
between expression ofp16 and pRb (Otterson et al, 1994; Shapiro
et al, 1995; Yeager et al, 1995; Sakaguchi et al, 1996; Ueki et al,
1996), suggesting the existence of a negative feedback loop
between these two cell cycle proteins. In a model for G1-S phase
progression, phosphorylation ofpRb by activated CDKs results in
the release of sequestered transcription factors and subsequent
transcription of genes required for S-phase. One of these genes
may bepi6 itself, as it has been found that p16 accumulates to a
high level in cells lacking functional pRb (Li et al, 1994). The p16
protein produced in this way would then be available to inhibit the
kinase activity of the CDKs and so transcription factors would
again be sequestered by pRb. If this model is correct, any defi-
ciency of pRb, whether due to alterations of the gene or other
changes affecting the protein levels, would be likely to result in
deregulated transcription of genes involved in G,-S progression
and include accumulation ofp16 protein.
Of the nineteen cases with reduced expression of pRb, only
-10% show corresponding accumulation (+++) ofp16 protein. For
example, case 3144 shows normal expression of pRb in normal
ducts and lack of expression in invasive cells, with a corre-
sponding increase in expression of p16 in the invasive cells rela-
tive to normal, which would agree with the proposed model
discussed above. The remaining 90% show a lower level or
complete loss of p16 expression and therefore, in common with
other studies (Wang and Becker, 1996), do not show an inverse
relationship between pRb andp16.
DISCUSSION
The assessment of the components of the GI regulatory pathway
by the technique of immunohistochemistry has the advantage of
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providing information on the levels of these proteins in individual
tumour cells. Results are not affected by contamination from
normal cells and do not rely on trying to predict the behaviour of
the protein solely from genetic information. However, the tech-
nique may be accompanied by several drawbacks. Depending on
the specificity of the antibody, positive nuclear reactivity may not
indicate the presence offunctional protein, as mis-sense mutations
or small deletions may be present that do not affect the epitopes
recognized by the antibody. Particularly forpl6, the immunocyto-
chemical reaction pattern of mutant proteins is unknown. In addi-
tion, the strong cytoplasmic staining that is often observed may
interfere with the interpretation of nuclear reactivity. The biolog-
ical meaning ofthis cytoplasmic staining is not clear.
Involvement of the G1 regulatory pathway in breast
carcinogenesis
When the above analyses of the individual components of the G,
regulatory pathway are considered together, it is apparent that in a
majority of cases studied there is a defect in some part of the
pathway, which confirms its importance in breast carcinogenesis.
The final column in Table 1 details which components for each
case are thought to be aberrantly expressed. This was determined
by making the following assumptions: (1) that reduced expression
ofpRb (- or +) and/or lack of nuclear staining was abnormal; (2)
that increased expression ofcyclin Dl (++ or +++) was abnormal;
and (3) that decreased expression of p16 (- or +) was abnormal.
Cyclin Dl appears to be the component most commonly affected,
with overexpression in -49% cases, which is similar to results
obtained elsewhere (Gillett et al, 1996). Reduced expression of
pRb is found in -46% cases and reduced expression of p16 is
found in -37% cases. Only three cases (228, 1565 and 2939)
appeared to have a completely normal expression profile for all
threeproteins.
Although disruption of more than one member of this pathway
would seem unnecessary for the tumour, there is some evidence
for the occurrence of oncogenic aberrations ofcyclin DI concur-
rently with loss of p16 (Lukas et al, 1995a) or loss of pRb
(Welcker et al, 1996). As it is expected that each of these muta-
tions is unequal, the most likely order of events in the latter case
would involve deregulation ofthe D-cyclins contributing to clonal
expansion of the original tumour, followed by subsequent loss of
pRb causing complete disruption of the G, checkpoint and
providing the tumour with an additional growth advantage.
Apart from cases 3144 and 3041, which show differential
expression of pRb in the in situ and invasive components of the
tumour, the staining patterns using all three antibodies give
concordant results between these two components in all of the
remaining cases. This suggests that if any aberrations of these cell
cycle-regulatory proteins have occurred during the formation of
the tumour, they are already present at the DCIS stage and are not
involved in bringing about progression from in situ to invasive
disease, if indeed such a progression exists.
Role of cyclin Dl in breast cancer
The role played by cyclin Dl in breast carcinogenesis and its
potential use as a prognostic marker have been the focus of many
studies. Additional information on the role cyclin Dl plays in the
normal situation has recently come to light. Studies on knockout
mice have shown that, although the protein is not essential for
survival, it is important for the response ofthe breast to hormones
during pregnancy (Sicinski et al, 1995). The mammary glands of
mice lacking cyclin DI fail to undergo the intense proliferation
induced by the ovarian steroids that normally accompanies preg-
nancy, confirming that cyclin Dl plays a critical role in the regula-
tion ofmammary epithelial proliferation.
Other studies have been suggestive ofa role for cyclin DI over-
expression in transformation of breast epithelial cells. In a recent
publication looking at a range of preinvasive and invasive breast
lesions (Weinstat-Saslow et al, 1995), cyclin DI mRNA was found
to be overexpressed in DCIS and invasive cases, but not in cases of
atypical ductal hyperplasia (ADH). However, there appears not to
be a straightforward relationship between cyclin DI and prog-
nosis. Early studies related cyclin DI amplification to poor prog-
nosis (Schuuring et al, 1992), consistent with the idea that an
increase in expression can enhance cell growth and provide the
cell tumour with a selective advantage. It is, however, possible that
amplification ofthe gene represents general genomic instability of
the tumour, or that other genes in the amplicon are exerting an
effect resulting in poor prognosis. A number of more recent
studies have indicated that overexpression ofcyclin DI, curiously,
is associated with less aggressive tumours and a better prognosis
in a range of cancers. In a recent immunohistochemical study
assessing cyclin Dl expression in archival invasive breast tumours
(Gillett et al, 1996), moderate/strong staining for cyclin DI was
associated with improved survival. This is perhaps surprising as it
is assumed that cells with increased levels of cyclin DI would be
more likely to undergo deregulated proliferation, contributing to
development of neoplasia. A similar effect has been observed in
non-small-cell lung cancer in which cyclin Dl overexpression was
associated with a lower risk oflocal relapse (Betticher et al, 1996)
and with superficial rather than invasive stages in bladder cancer
(Bringuier et al, 1996). One possible explanation given for this is
that mutations in other genes, for example Rb, might be having a
dominating influence on clinical outcome in cases with low levels
of cyclin Dl and associated poor prognosis. Perhaps related to
these results is the finding that in neuronal cells the absolute level
of cyclin Dl is critical; moderate overexpression causes growth
stimulation, whereas high overexpression results in apoptotic cell
death (Kranenburg et al, 1996). If the same explanation could be
extended to tumours, then the apparent paradox could be
explained. For those tumours in which the cyclin Dl level exceeds
the threshold for a positive regulatory effect, the cells may become
apoptotic, with a resultant improved prognosis relative to tumours
with lower levels ofcyclin Dl. A number ofother in vitro studies
have provided an insight into the negative growth-regulatory
effects of cyclin D1. Work by Han et al (1995) on a human
mammary epithelial cell line showed that an increased expression
of cyclin- Dl resulted in inhibition rather than enhancement of
growth. Another possible explanation for such opposite effects
could be that a moderate increase in cyclin Dl expression may
have a positive effect, but a high level may be toxic to the cell. In
support of this, transient overexpression of cyclin Dl in normal
diploid fibroblasts efficiently blocks progression into S-phase
(Atadja et al, 1995). The fact that cyclin DI forms a ternary
complex with proliferating cell nuclearantigen (PCNA), p21 and a
cyclin-dependent kinase (CDK) might provide a possible mecha-
nism forthis, as high levels ofcyclin DI might negatively regulate
cell growth by stabilizing the CDK inhibitor p21 or by inhibiting
DNA replication and repair by sequestering the PCNA protein. It
can be imagined that the positive or negative regulatory function
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of cyclin Dl depends upon the relative levels of all of these
proteins and on the cell type being studied.
In order to further elucidate the possible prognostic significance
ofaberrations ofcell cycle components in breast carcinogenesis, it
will be necessary to carry out studies similar to this one on a larger
sample size and look for corfelations between protein expression
and survival data.
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